Aperio Group LLC cut its holdings in Amedisys Inc (NASDAQ:AMED) by 21.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,369 shares of the health services provider’s stock after selling 4,699 shares during the quarter. Aperio Group LLC owned 0.05% of Amedisys worth $972,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of AMED. Russell Investments Group Ltd. grew its holdings in shares of Amedisys by 662.7% in the second quarter. Russell Investments Group Ltd. now owns 276,808 shares of the health services provider’s stock valued at $17,387,000 after purchasing an additional 240,513 shares in the last quarter. Balyasny Asset Management LLC purchased a new position in shares of Amedisys in the second quarter valued at $7,736,000. TimesSquare Capital Management LLC grew its holdings in shares of Amedisys by 15.7% in the second quarter. TimesSquare Capital Management LLC now owns 731,670 shares of the health services provider’s stock valued at $45,956,000 after purchasing an additional 99,380 shares in the last quarter. Timpani Capital Management LLC purchased a new position in shares of Amedisys in the second quarter valued at $4,924,000. Finally, Vanguard Group Inc. grew its holdings in shares of Amedisys by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,369,678 shares of the health services provider’s stock valued at $121,067,000 after purchasing an additional 63,238 shares in the last quarter. 93.94% of the stock is owned by hedge funds and other institutional investors.
A number of research firms recently weighed in on AMED. Mizuho lowered shares of Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a report on Wednesday, July 26th. Benchmark Co. reissued a “hold” rating on shares of Amedisys in a report on Thursday, November 9th. Robert W. Baird restated a “hold” rating and issued a $50.00 price target on shares of Amedisys in a research report on Wednesday, October 4th. Bank of America Corporation assumed coverage on Amedisys in a research report on Monday, August 21st. They issued a “neutral” rating and a $55.00 price target for the company. Finally, BidaskClub upgraded Amedisys from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Amedisys currently has a consensus rating of “Hold” and an average price target of $61.00.
Shares of Amedisys Inc (NASDAQ:AMED) opened at $55.01 on Monday. The stock has a market capitalization of $1,866.86, a price-to-earnings ratio of 26.32, a P/E/G ratio of 1.33 and a beta of 0.68. Amedisys Inc has a 52-week low of $38.00 and a 52-week high of $65.91. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.33 and a quick ratio of 1.33.
Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.02. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The business had revenue of $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. During the same period last year, the company earned $0.36 earnings per share. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. analysts anticipate that Amedisys Inc will post 2.23 EPS for the current year.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.